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To examine the efficacy and safety of corneal cross linking (CXL) for stabilisation of progressive 41 
keratoconus.  42 
Design 43 
Observer-masked, randomized, controlled, parallel group superiority trial. 44 
Participants 45 
60 participants aged 10-16 years with progressive keratoconus. One eye of each patient was deemed 46 
the study eye.  47 
Intervention 48 
According to randomization the study eye received either CXL plus standard care or standard care 49 
alone, with spectacle or contact lens correction as necessary for vision.  50 
Main outcome measures 51 
The primary outcome was K2 in the study eye as a measure of the steepness of the cornea at 18 52 
months. Secondary outcomes included keratoconus progression defined as 1.5 dioptres (D) increase 53 
in K2, visual acuity, keratoconus apex corneal thickness and quality of life.  54 
Results 55 
Of 60 participants, 30 were randomized to CXL and standard care groups. Of these, 30 patients in the 56 
CXL group and 28 patients in the standard care group were analyzed. The mean (SD) K2 in the study 57 
eye 18 months post-randomization was 49.7D (3.8) in CXL and 53.4D (5.8) in standard care groups. 58 
The adjusted mean difference in K2 in the study eye was -3.0D (95% CI -4.9 to -1.1; p=0.002), 59 
favouring CXL. Uncorrected and corrected differences in logMAR vision at 18 months was better in 60 
eyes receiving CXL, -0.31 (95% CI -0.50 to -0.11, p=0.002) and -0.30 (95% CI -0.48 to -0.11, p=0.002). 61 
Keratoconus progression in the study eye occurred in 2 patients (7%) randomized to CXL compared to 62 










patients in the CXL arm had 90% (OR 0.1, 95% CI 0.02 to 0.48, p= 0.004) lower odds of experiencing 64 
progression compared to those on standard care. Quality of life outcomes were similar in both 65 
groups. 66 
Conclusions 67 
CXL arrests progression of keratoconus in the great majority of young patients. These data suggest 68 
that CXL should be considered as first line treatment in progressive disease. If the arrest of 69 
keratoconus progression induced by CXL is sustained in longer follow up, there may be particular 70 
benefit in avoiding a later requirement for contact lens wear or corneal transplantation. 71 











Keratoconus, characterized by distortion and thinning of the cornea, is usually bilateral but can be 74 
asymmetric. In its early stages keratoconus causes worsening of vision due to increasing myopia and 75 
irregular astigmatism: spectacle correction can only provide good visual acuity in early disease, until 76 
increasingly irregular astigmatism requires correction with rigid contact lenses for best vision. If 77 
lenses are not tolerated these individuals can be functionally blind in affected eyes. Patients with 78 
more advanced keratoconus lose contact lens-corrected visual acuity as a result of corneal 79 
opacification and require corneal replacement by transplantation. Reported keratoconus prevalence 80 
is 1:375 (265 per 100 000) in the Netherlands,1 1:84 in Australian 20 year olds2 and as high as 1:45 in 81 
some ethnic groups.3 Onset is rare before the age of 10 years and the age at diagnosis is usually 82 
between 15 and 30 years, with progression in affected eyes until spontaneous stabilization in the mid-83 
30s. Diagnosis and monitoring of progression is by corneal tomography, which quantifies irregularity 84 
of corneal curvature and corneal thickness. 85 
While standard care involves treatment of the refractive consequences of keratoconus or 86 
replacement of the diseased cornea by a transplant, the concept of arresting progression of 87 
keratoconus at an early stage when there is still good unaided or spectacle-corrected vision is 88 
relatively recent. Corneal cross linking (CXL) has been reported to be effective in arresting 89 
keratoconus progression in the majority of treated adult eyes based on evidence from three 90 
randomized controlled trials,4-6 but the findings are limited by uncertainty (wide confidence intervals) 91 
and likely risk of bias.7 CXL increases the biomechanical rigidity of the cornea but direct ultrastructural 92 
evidence of the mechanism of action has not been found.8 93 
Keratoconus is often more advanced if first diagnosed in children than in adults, and some suggest 94 
faster subsequent disease progression.9-11 A number of retrospective observational studies of CXL in 95 
younger patients, with varying age ranges and duration of follow-up, have reported a beneficial effect 96 
of CXL.12-17 Treatment of young patients by conventional (‘Dresden’) and accelerated CXL protocols 97 
have been reported to be similarly effective.18 However more robust randomized evidence is required 98 









As subclinical or early keratoconus can be detected by tomography in young patients, and if CXL can 100 
halt disease progression, there is an opportunity to stabilize disease at an early stage, prior to the 101 
requirement for contact lenses or corneal transplantation. The Keralink randomised controlled trial 102 
assesses the efficacy and safety of CXL in 10 to 16 year olds with progressive keratoconus to 103 
determine whether CXL plus standard care stabilizes progressive keratoconus, is associated with 104 
better vision and quality of life and is safe compared with standard care alone. 105 
 106 
Methods 107 
Study design and participants 108 
The Keralink trial is an observer-masked, individually randomized, controlled, parallel group 109 
superiority trial. The trial protocol is published19 and available online as follows. 110 
https://www.journalslibrary.nihr.ac.uk/programmes/eme/142318/#/ 111 
Keralink was approved by the UK Health Research Authority, the Medicines and Healthcare Products 112 
Regulatory Agency and ethics approval was granted by the Brent Ethics Committee (reference 113 
16/LO/0913). The trial adhered to the tenets of the Declaration of Helsinki. Consecutive newly 114 
referred patients at four UK hospitals aged 10-16 years with suspected keratoconus were identified. 115 
Keratoconus was confirmed in one or both eyes by corneal tomography (Pentacam HR, Oculus GmbH, 116 
Wetzlar, Germany) and patients were monitored 3-monthly for progression. To differentiate true 117 
keratoconus progression from measurement artefact, an increase over an interval of at least three 118 
months in the mean corneal power in the steepest meridian (K2) or in the steepest corneal power 119 
(Kmax) of at least 1.5 D in one or both eyes was used as the threshold for eligibility.20 For each 120 
patient, the eye with the more advanced keratoconus at baseline was categorized as the study eye, 121 
unless that eye had undergone prior surgery such as corneal transplantation. Patients with corneal 122 
apex thickness <400 μ were excluded (therefore all study eyes had keratoconus classified as Amsler-123 
Krumreich stage I and II21). Additional exclusion criteria were corneal opacification, corneal apex 124 










prior to follow-up tomography examinations. Written informed consent was obtained from parents of 126 
all recruited participants. This trial is registered in the European Union clinical trials register (EudraCT 127 
2016-001460-11). 128 
Baseline assessment 129 
At baseline all patients were assessed as set out in Table 1. 130 
Randomization and masking 131 
Randomization used a minimization algorithm incorporating a random element with minimization 132 
factors of treatment centre and whether progression was confirmed in one or both eyes at 133 
randomization. After verification of eligibility a web-based randomization service 134 
(https://www.sealedenvelope.com) issued a randomization assignment. Participants were 135 
randomized in a 1:1 ratio to either CXL or standard care in the study eye. Due to the invasive nature 136 
of the CXL intervention, neither the trial participants nor the treating clinicians were masked to the 137 
treatment allocation. However, optometrists performing all outcome examinations and questionnaire 138 
evaluations were masked as to the randomized allocation. The treating clinicians were masked to 139 
primary outcome data (K2) measured by optometrists during the follow-up assessments. 140 
CXL procedure 141 
CXL was performed under local or general anaesthesia in one or both eyes (according to whether 142 
progression was confirmed in one eye or both). Following removal of the corneal epithelium with a 143 
spatula and administration of riboflavin drops (Vibex Rapid, Avedro, Waltham, USA) every 2 minutes 144 
for 10 minutes, ultraviolet light was applied using standardized parameters of 10 mW/cm2 for a 5.4 145 
J/cm2 total energy dose administered over9 min in a continuous manner (Avedro KXL).19 At 146 
completion of the procedure a protective contact lens was applied to the eye until corneal 147 
epithelialisation was complete. Subsequent management with topical steroid and topical antibacterial 148 
prophylaxis is described elsewhere.19 Participants randomized to CXL received spectacle or contact 149 
lens correction as necessary for the study eye, as in the Standard care comparator trial arm. 150 










The trial control arm was standard management alone, including refraction testing with provision of 152 
glasses and/or contact lens fitting for one or both eyes as required for best-corrected visual acuity. 153 
Participants randomized to standard care with confirmed progression (see below) were offered cross-154 
over to the CXL arm; this was undertaken no earlier than 9 months post-randomization.19 155 
Outcomes.  156 
The most important parameters used in the assessment of progression of keratoconus are the 157 
curvature of the cornea (measured as dioptre power K), corneal thickness in µm, refraction, and best-158 
corrected visual acuity. The primary outcome measure was mean corneal power in the steepest 159 
meridian (K2) in the study eye, measured using corneal tomography at 18 months post-160 
randomization. The mean of triplicate K2 measurements at baseline and at each follow-up 161 
assessment was used in analyses. Secondary outcomes were keratoconus progression, defined as K2 162 
increase >1.5D, unaided and best-corrected visual acuity, corneal thickness at the keratoconus apex 163 
and vision-related quality of life (QoL) assessed by CVAQC22 and CHU9D23 questionnaires. Safety was 164 
documented in all participants.  165 
Statistical analysis 166 
All study analyses were done according to a predefined statistical analysis plan, reported elsewhere.24 167 
On the basis of a previous study of CXL in adults6 we estimated that a sample size of 60 patients 168 
would be required to detect a difference between the two groups of 1.5D in the change in K2 at 18 169 
months after randomization. These calculations were based on a common SD of 1.5D, 90% power and 170 
a type 1 error rate of 5%. Additionally we allowed for a loss-to-follow-up rate of 24%. All efficacy 171 
analyses were conducted following the intention to treat (ITT) principle where all randomized 172 
patients were analysed in their allocated group whether or not they received their randomized 173 
treatment. If a tomography scan was categorized as being of unreliable quality by a red flag indicator 174 
on the Pentacam software then the K2 measurement from that scan was not used. For the primary 175 
analysis, the mean K2 at each visit was calculated using measurements from reliable scans only. Two 176 










associated red flag indicator (Fig 1). We did not perform multiple imputation as there were minimal 178 
missing data. 179 
A multilevel repeated measures linear regression model was used to estimate the difference between 180 
the treatment groups in K2 values at 18 months. The model included fixed effects for K2 at 181 
randomization, treatment group, time, treatment by time interaction, and the minimisation factors 182 
centre and number of eyes progressed at randomization. A random patient effect was included to 183 
take account of clustering within patients. The model coefficients were estimated using the robust 184 
standard errors technique, to allow for unequal variances in the two randomised groups. Model 185 
assumptions were assessed using residual plots. We carried out pre-specified subgroup analysis by 186 
whether a history of atopy was reported and by ethnicity. All statistical tests used a two-sided p value 187 
of 0.05, unless otherwise specified. There were no formal adjustments of p values as per our SAP. 188 
Two-sided 95% confidence intervals were presented for all estimates. Findings for the secondary 189 
outcomes are not corrected for multiple comparisons.25 The confidence intervals and statistical tests 190 
are considered to provide supportive evidence in relation to the primary objective and additional 191 
clinical characterisation of treatment effects. STATA/MP 15.0 was used for all analyses. 192 
 193 
Results 194 
Between 28 October 2016 and 26 September 2018, 240 patients were screened for eligibility, 60 of 195 
whom were randomly assigned to either CXL or standard care in the study eye. The number of 196 
participants recruited and included in the analysis is set out in Fig 1. Two patients on standard care 197 
withdrew from the trial before their three month follow-up visit. A further two patients were lost-to-198 
follow-up or discontinued the study after the three month visit, but their data were included in the 199 
ITT analysis. One patient in the CXL group did not undergo the randomized procedure having 200 
withdrawn consent, but continued follow-up assessments as per protocol.  201 
Baseline demographic and ocular characteristics are shown in Table 2. Patients randomized to CXL 202 










ethnic group (40% vs 17%) compared to those in standard care.  Mean (SD) age of the participants 204 
was similar in both treatment arms: 15 (1.1) years in the CXL arm and 15 (1.6) in standard care. 205 
Overall, 45% were of south Asian or Asian British ethnicity. Seven patients (12%) had progression in 206 
both eyes meeting the eligibility criteria for randomization. For these patients, the eye with the most 207 
advanced disease was deemed to be the study eye and received randomized treatment. 68% of 208 
patients were using a refractive corrective aid at baseline - the majority (85%) using glasses, five 209 
patients used both glasses and contact lenses and one patient reported using only contact lenses. Of 210 
those using contact lenses, three patients reported using rigid contact lenses at baseline. Mean (SD) 211 
K2 in the study eye was 49 D (3.5) in patients randomized to CXL and 50 D (3.4) in standard care. The 212 
baseline measurements including uncorrected visual acuity, best-corrected visual acuity, apical 213 
corneal thickness and maximum keratometry (Kmax) for the study eye are summarized in Table 2. The 214 
table also includes baseline QoL scores of patients measured using the CVAQC and CHU9D 215 
questionnaires.  216 
Findings for the primary outcome, K2 in the study eye, are set out in Fig 2 and Table 3. At 18 months, 217 
CXL patients had a mean (SD) K2 of 49.7D (3.8) compared to 53.4D (5.8) in standard care patients. The 218 
adjusted difference of -3.0D (95% CI: -4.93 to -1.08) suggests that on average, patients who received 219 
CXL in the study eye had a K2 3D lower than those in standard care arm at 18 months post 220 
randomization. This difference is statistically significant (p=0.002). The 95% confidence interval 221 
contains the clinically important difference of 1.5D, which corresponds to keratoconus progression. 222 
Five patients crossed-over from standard care to CXL between 12 and 18 months (as per protocol 223 
provision) and one patient in the CXL arm did not undergo their allocated procedure. A further 224 
patient randomized to CXL was subsequently found to be ineligible for the trial. As the patient had 225 
already had CXL when this error was discovered, follow-up continued. Per-protocol analysis excluding 226 
this patient at baseline and patients at the time of cross-over did not change the observed ITT results. 227 
Data from patients were excluded at some visits from the mean K2 calculation due to tomography 228 










recognized that repeatability of tomography scans is reduced in eyes with advanced keratoconus.20,26 230 
In order to evaluate the impact of inclusion of these patients with advanced disease on the observed 231 
treatment difference we carried out exploratory sensitivity analysis on the primary outcome by 232 
including K2 measures from red-flagged scans of patients with advanced disease (see Supplementary 233 
material and Supplementary Fig 1). The difference in means between the treatment arms increased at 234 
18 months in Supplementary Fig 1 compared to that in Fig 2.  235 
Findings for the secondary outcomes are set out in Table 4. There was increasing difference in mean 236 
uncorrected and best-corrected visual acuity between the groups at follow-up visits (Fig 3A and B). 237 
Adjusted analysis shows that, on average, patients in CXL group had significantly lower logMAR values 238 
for uncorrected and best-corrected visual acuity compared to those on standard care (p=0.002 and 239 
0.002, respectively) (Table 4), indicating that patients randomized to CXL had significantly better 240 
visual acuity at 18 months. We found no significant differences at 18 months between the CXL and 241 
standard care groups in apical corneal thickness (Fig 3C) and refraction measured as spherical 242 
equivalent. Mean Kmax in the study eye at 18 months post-randomization was 57D (6.2) in the CXL 243 
arm and 60D (7.7) in standard care. The adjusted difference (95% CI) in Kmax of -2.11 (-4.81, 0.60) at 244 
18 months was not statistically significant (p=0.13). There were no significant differences in patients’ 245 
quality of life at 18 months as measured using CVAQC and CHU9D questionnaires. By 18 months, two 246 
patients (7%) in the CXL arm had experienced keratoconus progression, compared to 12 (43%) on 247 
standard care. The unadjusted odds ratio (OR) suggests that on average patients in the CXL arm have 248 
90% (OR 0.1, 95% CI 0.02 to 0.48, p= 0.004) lower odds of experiencing progression compared to 249 
those on standard care. Cox proportional hazards regression of time to progression suggests an 87% 250 
lower hazard for the CXL arm. Figure 4 shows the Kaplan-Meier plot of time-to-progression in the two 251 
arms. There were no serious adverse events (SAEs) reported during the trial.  252 
There was no significant interaction between treatment allocation and a history of atopy (p=0.59) or 253 
ethnicity (p=0.95). We also did post hoc comparison of those patients in whom progression occurred 254 










average age between the groups (p=0.31) and no significant association between progression and 256 
ethnicity (p=0.21). As these were not pre-specified analyses and in particular as the age of recruited 257 
patients was skewed towards the upper end of the range, this test might not be sufficiently sensitive 258 
to detect such an effect.  259 
 260 
Discussion 261 
In this observer masked randomized controlled trial involving young patients aged 10-16 years we 262 
found that at 18 months participants randomized to CXL plus standard care were less likely to have 263 
clinically significant progressive keratoconus and visual loss in the study eye than those treated with 264 
standard care alone. The primary trial outcome finding was the demonstration that, on average at 18 265 
months post-randomization, patients receiving CXL in the study eye had corneal power in the 266 
steepest meridian (K2) 3D lower than those receiving standard care, a statistically significant 267 
difference (p=0.002). In addition, the 95% confidence interval for the difference includes the clinically 268 
important difference of 1.5D, which was the trial protocol definition of keratoconus progression. We 269 
found no adverse events associated with CXL, suggesting also that this is a relatively safe intervention.  270 
The secondary outcomes demonstrating that efficacy of CXL in halting keratoconus progression was 271 
clinically important were (i) a significant difference in uncorrected and best-corrected visual acuity 272 
(p=0.002 and 0.002, respectively) between the trial arms, and (ii) the finding that only 2 patients (7%) 273 
randomized to CXL experienced keratoconus progression in the study eye compared to 12 (43%) in 274 
the standard care group at 18 months. Taken together these findings provide clear evidence of the 275 
efficacy of CXL in stabilizing keratoconus progression in 10 to 16 year olds.  276 
These findings are generally in keeping with data from RCTs reported in a Cochrane review comparing 277 
CXL with standard care for keratoconus in adult patients and reduce current uncertainty. In the three 278 
trials eligible for inclusion in that review the data suggest that eyes treated by CXL were less likely to 279 
have an increase in Kmax of 1.5D or more at 12 months compared to eyes treated with standard care. 280 










better uncorrected visual acuity (approximately 2 lines or 10 letters better) (MD -0.20, 95% CI: -0.31 282 
to -0.09; participants = 94; studies = 1, low quality evidence).7 The quality of the evidence was 283 
deemed low as it was largely derived from one trial at high risk of bias, the data on corneal thickness 284 
were inconsistent and adverse effects were frequent but mostly transient. No randomized trial of CXL 285 
in young patients has been reported. Uncontrolled observational studies of CXL in keratoconus 286 
patients <19 years have been published, each with limitations but each reporting effectiveness. 287 
Caporossi et al. reported an uncontrolled study of 152 keratoconus patients ranging in age from 10 to 288 
18 years, on whom follow up post-CXL was available on only 61% of patients. In addition to short-289 
term follow-up, the inclusion criteria included several parameters which are well recognised to be 290 
characterised by high inter-test variability. In this treated patient group, there was reduction of K2 by  291 
-0.4 D at 36 months suggesting stabilization.12 Vinciguerra et al reported 40 CXL-treated eyes in 292 
patients with progressive keratoconus aged 9-18 (mean 14.2) years in a non-randomized prospective 293 
study. Findings included reduced myopic spherical equivalent on refraction testing and reduction in 294 
mean K2 from 51.48 pre-CXL to 50.21 at 24 months.13 Our finding in the CXL-treated trial group of 295 
continued apical corneal thinning from baseline, although to a lesser extent than in the standard care 296 
group, is in keeping with other reports following CXL.6,7  297 
We were unable to demonstrate a significant improvement in quality of life between trial arms. 298 
Impact on quality of life (QoL) in keratoconus is significantly influenced by whether one or both eyes 299 
are affected,27,28 for which reason a major determinant of QoL in the trial is very likely to have been 300 
the vision in the non-study eye. Moreover, the problems with reduced contact lens tolerance as 301 
keratoconus progresses and the eventual need to have corneal transplantation have major impacts 302 
on QoL, and would not be expected in these trial participants with early keratoconus. Follow up of 303 
Keralink participants, including serial assessment of general and vision-related quality of life 304 
outcomes, will be continuing to four years post-randomization. 305 
 306 










people it is important to confirm the safety and efficacy of CXL in this population.10 A strength of this 308 
trial was that the upper eligible age limit was 16 years, compared to previous uncontrolled studies in 309 
young patients that included patients up to the age of 19 years. Demonstration of efficacy in the 310 
younger patients is of additional importance because corneal tomography is becoming more widely 311 
available in community settings, which will in turn lead to younger age at diagnosis and referral to 312 
secondary care clinics. A further strength of our study is the use of a measurement protocol that 313 
addresses the key problem of measurement variability in corneal tomography, the standard imaging 314 
technique for assessing progression of keratoconus. Repeatability of most tomographic parameters is 315 
good in mild keratoconus but worsens as disease progresses, in particular the single steepest power 316 
measurement Kmax.20,26 To obtain data reliably identifying change we used K2, the mean corneal 317 
power in the steepest corneal meridian, rather than Kmax as the primary outcome measure. As K2 is 318 
a measure of the mean curvature in the central 3mm zone of the cornea, change in K2 would be 319 
expected to correlate with change in vision; Kmax is the maximum curvature/power, at whatever 320 
point that might be, and may not be close to the visual axis - thus and as found in this trial it can 321 
correlate poorly with vision effects of the ectasia. As K2 represents a mean value it would inherently 322 
allow more reliable discrimination between change of functional significance between study groups. 323 
Use of the mean of triplicate readings for all assessments - at trial eligibility screening, baseline and 324 
outcome examinations - is a further methodological strength which gives validity to the finding of 325 
differences in outcomes between the two trial groups. Finally, the definition of progression post-326 
randomization, a K2 increase >1.5 dioptres, corresponds to change in corneal power of visual 327 
significance.  328 
 329 
As there is known ethnic variation in prevalence of severe keratoconus, a limitation of our study may 330 
be the applicability of our findings to other populations. South Asian ethnicity is strongly associated 331 
with keratoconus in the UK29,30 and accounted for 45% of patients recruited to this trial, a very 332 










demonstrate an interaction between treatment effect and ethnicity. An unanticipated measurement 334 
problem which emerged during our trial is that measurements of K2 in those eyes with most 335 
significant progression were in some cases marked with a red flag by Pentacam device software. In 336 
two patients in the standard care group at month 18 measurements from all three scans were 337 
excluded for this reason, although not specified in the trial protocol. However, sensitivity analyses of 338 
our primary outcome of K2 including all red flag measurements (Supplementary Fig. 1) and also a per 339 
protocol analysis did not change our conclusions. 340 
 341 
Despite documented progression of 1.5D prior to randomization, it is of interest that only 43% of 342 
subjects receiving standard care subsequently progressed clinically during the 18-month follow up 343 
period. This suggests that the proportion of keratoconus patients that have spontaneous stabilisation 344 
may be higher than expected, at least in 10 to 16 year olds. Earlier reports from uncontrolled studies 345 
of effectiveness of CXL in halting keratoconus progression in young patients should now be re-346 
evaluated in the light of this observation. Even though CXL is a relatively safe procedure, it is 347 
important that children with non-progressive keratoconus are not managed by CXL. 348 
 349 
Keralink provides high quality randomized evidence of efficacy of CXL in arresting progression of 350 
keratoconus in the great majority of young patients. Our data support a change in practice such that 351 
CXL should be considered for disease stabilisation in young patients with evidence of keratoconus 352 
progression. In such patients with early onset keratoconus in whom there is potential for further 353 
progression to the end of the third decade, there may be particular benefit in avoiding the later 354 
requirement for contact lens wear or corneal transplantation. There is emerging evidence that CXL 355 
can reduce the risk of transplantation.31,32  356 
Key questions to investigate are whether the arrest of keratoconus progression induced by CXL is 357 
permanent and whether an increasing proportion of those receiving standard care significantly 358 










these questions. A health economic evaluation modelling the impact of CXL in young patients, beyond 360 
the scope of our trial and taking into consideration Keralink longer term follow-up data, is warranted. 361 
The first cost-effectiveness analyses based on adult CXL studies reported a high likelihood of cost 362 
effectiveness.33,34 CXL is an efficacious  and safe intervention which stabilises keratoconus progression 363 
in young patients; in the event that stabilisation is sustained our findings may be the first line of 364 
evidence justifying the screening of young patients with astigmatism for keratoconus, and 365 
consideration of early CXL before there has been significant visual loss.  366 
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Figure legends 512 
 513 
Figure 1: Trial profile (Consort diagram) 514 
All 58 patients who had baseline K2 measurement and at least one follow-up were included in the 515 
mixed model for the primary outcome analysis.  516 
*Two participants who withdrew before the 3 month follow-up examination could not contribute 517 
data to the primary outcome, but were included in the baseline characteristics table.  518 
**One further patient randomized to CXL was subsequently found to have pre-randomization K2 519 
increase of 1.2 D and therefore did not meet the 1.5D K2 increase criterion for trial eligibility. As the 520 
patient had already had CXL in the study eye when this error was discovered we continued to follow-521 
up the patient; a protocol deviation was recorded. 522 
 523 
Figure 2: K2 in the study eye in patients in Corneal cross-linking (CXL) and Standard care 524 
groups in primary outcome population at study visit intervals 525 
K2 is the mean corneal power in the steepest meridian of the cornea, measured in dioptres (D). Data 526 
are means. Error bars represent 95% confidence intervals of the mean. 527 
 528 
Figure 3: Uncorrected visual acuity (A), best-corrected visual acuity (B), and corneal thickness 529 
at the corneal apex (C) in the study eye, in Corneal cross-linking (CXL) and Standard care groups at 530 
study visit intervals  531 
Data are means. Error bars represent 95% confidence intervals of the mean. 532 
 533 
Figure 4: Kaplan-Meier plot of time to keratoconus progression in Corneal cross-linking (CXL) 534 
and Standard care groups 535 











Corneal tomography Measurement of corneal power in steepest 
meridian (K2) and maximum power (Kmax), 
triplicate1 
Visual acuity Unaided or with preferred correction (logMAR) 
 
Refraction Subjective, both eyes 
 
Apical corneal thickness measurement Ultrasonic pachymetry2 and Pentacam imaging 
 
Quality of life Vision-related (CVAQC)3, generic paediatric 
health outcome (CHU9D)4 
 
Baseline assessments of the study eye and quality of life 
 
1 Mean of triplicate measurements were used in assessment of progression for eligibility, baseline 
and all follow-up assessments. 
 
2 Pachymate DGH55 (DGH Technology Inc., Exton, PA, USA) 
 
3CVAQC: Cardiff Visual Ability Questionnaire for Children.17 
 













CXL Standard care Total  
 (n = 30)  (n = 30) (n = 60) 
MINIMIZATION FACTORS       
Treatment centre       
   Moorfields  25 (84%) 25 (84%) 50 (83%) 
   Sheffield 2 (7%) 4 (13%) 6 (10%) 
   Liverpool 1 (3%) 0 (0%) 1 (2%) 
   Royal Gwent 1 (3%) 0 (0%) 1 (2%) 
   Manchester 1 (3%) 1 (3%) 2 (3%) 
Number of eyes with progression       
   One eye 27 (90%) 26 (87%) 53 (88%) 
   Two eyes 3 (10%) 4 (13%) 7 (12%) 
PATIENT CHARACTERISTICS       
Age (years) 15.2 (1.1) 15.2 (1.6) 15.2 (1.4) 
Gender       
   Male 25 (83%) 19 (63%) 44 (73%) 
   Female 5 (17%) 11 (37%) 16 (27%) 
Ethnicity       
   White 12 (40%) 5 (17%) 17 (28%) 
   Mixed 4 (13%) 2 (7%) 6 (10%) 
   Asian or Asian British 10 (34%) 17 (56%) 27 (45%) 
   Black or Black British 3 (10%) 4 (13%) 7 (12%) 
   Other ethnic groups 1 (3%) 2 (7%) 3 (5%) 
Use of refractive correction aid       
   No 9 (30%) 10 (33%) 19 (32%) 
   Yes 21 (70%) 20 (67%) 41 (68%) 
Refractive correction aid       
   Glasses 18 (60%) 17 (57%) 35 (58%) 
   Contact Lenses 0 (0%) 1 (3%) 1 (2%) 
   Both 3 (10%) 2 (7%) 5 (8%) 
Type of lenses       
   Soft lenses 3 (10%) 0 (0%) 3 (5%) 
   RGP 0 (0%) 3 (10%) 3 (5%) 
Family history of keratoconus       
   No 24 (80%) 28 (93%) 52 (87%) 
   Yes 6 (20%) 2 (7%) 8 (13%) 
History of atopy       
   No 20 (67%) 14 (47%) 34 (57%) 
   Yes 10 (33%) 16 (53%) 26 (43%) 








K2 (D) 49.1 (3.5) 50.2 (3.4) 49.7 (3.5) 
Kmax (D) 56.0 (4.8) 57.2 (5.7) 56.6 (5.3) 
Uncorrected visual acuity (logMar) 0.6 (0.4) 0.7 (0.4) 0.7 (0.4) 
Best-corrected visual acuity (logMar) 0.5 (0.4) 0.5 (0.4) 0.5 (0.4) 
Apical corneal thickness (µm) 512 (47.9) 507 (41.2) 509 (44.5) 
Refraction (spherical equivalent) (D) -0.6 (2.3) -1.0 (1.6) -0.8 (2.0) 
CVAQC score -1.1 (1.0) -1.2 (1.1) -1.2 (1.0) 
CHU9D utility score 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 
 
Baseline demographic and ocular characteristics of the intention-to-treat population 
 




















n  Mean (SD) n  Mean (SD) 
Primary outcome  
K2 (D) - ITT 
population 
30 49.7 (3.8) 23 53.4 (5.8) 
-3.00 
(-4.93 to -1.08) 
0.002 
Sensitivity analysis of primary outcome 
K2 (D) - PP 
population 
28 49.4 (3.4) 19 53.2 (5.8) 
-3.23  
(-5.21 to -1.26) 
0.001 
K2 (D) (including all 
scans with red flags)  





K2 in study eye at 18 months post-randomization, by treatment group 
 
1
Adjusted difference is based on 58 patients in the Intention-To-Treat (ITT) mixed model, 55 in the Per Protocol 
(PP) model and 58 in the model including tomography scans with red flags who had a baseline K2 
measurement and at least one follow-up examination. 
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n  Mean (SD) n  Mean (SD) 
Apical corneal 
thickness (µm)  
28 501.8 (38.0) 22 479.9 (46.3) 
16.37 





29 0.5 (0.3) 25 0.8 (0.6) 
-0.31  





29 0.4 (0.4) 25 0.6 (0.6) 
-0.51 





30 -0.6 (2.0) 25 -0.3 (2.3) 
-0.75 
 (-1.69 to 0.18) 
0.25 




CVAQC score3 29 -1.2 (0.8) 25 -1.1 (0.9) 
-0.26  




28 1.0 (0.1) 25 0.9 (0.1) 
0.02 
(-0.017 to 0.05) 
0.14 
  n  n (%)  n  n (%)  
Unadjusted odds 




30 2 (7%) 28 12 (43%) 
0.10 















30 See Figure 4  30 See Fig 4  
0.13 
 (0.03 to 0.59) 
0.008 
 
Secondary outcomes at 18 months, by treatment group 
 
1
Adjusted for baseline and minimization factors site and number of eyes with progression at baseline. 
2
Lower logMAR scores correspond to better visual acuity. 
3 




Higher questionnaire scores indicate better outcome.  
5

































30 30 28 28 3CXL
30 28 19 16 4Standard care
Number at risk
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In 10-16 year old patients with confirmed progressive keratoconus, cross-linking had a significant 
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